Cargando…
Glycogen Synthase Kinase-3: A Promising Therapeutic Target for Fragile X Syndrome
Recent advances in understanding the pathophysiological mechanisms contributing to fragile X syndrome (FXS) have increased optimism that drug interventions can provide significant therapeutic benefits. FXS results from inadequate expression of functional fragile X mental retardation protein (FMRP)....
Autores principales: | Mines, Marjelo A., Jope, Richard S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Research Foundation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3205455/ https://www.ncbi.nlm.nih.gov/pubmed/22053151 http://dx.doi.org/10.3389/fnmol.2011.00035 |
Ejemplares similares
-
Regulation of Cell Survival Mechanisms in Alzheimer's Disease by Glycogen Synthase Kinase-3
por: Mines, Marjelo A., et al.
Publicado: (2011) -
Glycogen Synthase Kinase-3 in the Etiology and Treatment of Mood Disorders
por: Jope, Richard Scott
Publicado: (2011) -
GSK3 Influences Social Preference and Anxiety-Related Behaviors during Social Interaction in a Mouse Model of Fragile X Syndrome and Autism
por: Mines, Marjelo A., et al.
Publicado: (2010) -
Impairments in cognition and neural precursor cell proliferation in mice expressing constitutively active glycogen synthase kinase-3
por: Pardo, Marta, et al.
Publicado: (2015) -
Lipopolysaccharide-induced interleukin-6 production is controlled by glycogen synthase kinase-3 and STAT3 in the brain
por: Beurel, Eléonore, et al.
Publicado: (2009)